[12] Patent
[11] Patent No.:GC0004518  
[45] Date of Publishing the Grant of the Patent: 31/Dec /2016                32/2016  
Number of the Decision to Grant the Patent:2016/89504
Date of the Decision to Grant the Patent:14/Dec/2016

[21] Application No.:GCC/P/2004/3428

[22] Filing Date:2/5/2004

[30] Priority:

[33] State [32] Priority date [31] Priority No.
EP
EP
2/5/2003
6/5/2003
PCT/EP03/04608
PCT/EP03/04729

[72] Inventors:1- Wolfgang Sohngen،2- Wolf-Dieter Schleuning،3- Robert Medcalf،4- Mariola Sohngen

[73] Owner: H. Lundbeck A/S, Ottiliavej 9, 2005 , Valby, Denmark

[74] Agent: Saud M. A. Shawwaf Law Office

  

 

  

[51]IPC:
Int. Cl.7: [C/C07](A 61 K 38/49 )

[56] Cited Documents:

-EP 0352119 A2 (MERCK & CO.INC.) 24 January 1990
-WO 03037363 A2 (PAION GMBH) 08 May 2003
-EP 1308166 A1 (PAION GMBH) 07 May 2003
-NORRMAN, Bo. et al. Proteolytically induced variations in the enzymatic properties of tissue plasminogen activator Activations, inactivations and reactivations. Eur. J. Biochem. 1986, Vol.159, pages7- 13.
 
Examiner: PH. Mohammad S. AlMousa

[54] INTRAVENOUS INJECTION OF NON-NEUROTOXIC PLASMINOGEN ACTIVATORS FOR THE TREATMENT OF STROKE
[57] Abstract: The invention refers to the use of non-neurotoxic plasminogen activating factors, e.g. from Desmodus rotundus (DSPA) or of genetically modified plasminogen activating factors, in particular of human origin, for the production of a pharmaceutical for injection for the therapeutic treatment of stroke in humans.
No. of claims: 7     No. of figures: 26


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.